Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.80 (0.78%)
Bid:
100.20
Ask:
105.80
Spread: 5.60 (5.589%)
Market Cap: £170.50m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Result of Equity Issue

17 Jan 2011 17:28

RNS Number : 6170Z
Yule Catto & Co PLC
17 January 2011
Β 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

Β 

Yule Catto & Co plc

Β 

17 January 2011

Β 

Result of Rights Issue

Β 

Yule Catto & Co plc (the "Company") announces that as at 11.00 a.m. on 17 January 2011, being the latest time and date of receipt for acceptance and payment in full, it had received valid acceptances in respect of 186,742,556 New Ordinary Shares, representing 96.15 per cent. of the total number of New Ordinary Shares offered to Shareholders, pursuant to the Rights Issue announced by the Company on 13 December 2010.

It is expected that the New Ordinary Shares in uncertificated form will be credited to CREST accounts of persons entitled thereto on 18 January 2011 and that definitive share certificates in respect of New Ordinary Shares in certificated form will be dispatched to Shareholders entitled hereto by no later than 25 January 2011. It is expected that the New Ordinary Shares will commence trading fully paid on the London Stock Exchange's main market for listed securities at 8.00Β a.m. on 18 January 2011.

As disclosed in Part IV of the combined circular and prospectus published by the Company in connection with the Rights Issue and sent to Shareholders on 13Β DecemberΒ 2010 (the "Prospectus"), the Joint Bookrunners will each severally use their reasonable endeavours to procure subscribers for the balance of 7,475,026Β New Ordinary Shares not validly taken up under the Rights Issue, on and subject to the terms and conditions agreed with the Company in the Underwriting Agreement. A further announcement as to the number of New Ordinary Shares for which subscribers have been so procured will be made in due course.

Β 

Unless otherwise defined in this announcement, capitalised terms shall have the meaning given to them in the Prospectus.

Β 

Contacts

For further information please contact:

Β 

Yule Catto & Co plc Tel: +44(0) 1279 442 791

Adrian Whitfield, Chief Executive Officer

David Blackwood, Group Finance Director

Β 

HSBC Tel: +44 (0) 20 7991 8888

Sole financial adviser to Yule Catto

Charles Packshaw

Oliver Smith

Β 

Sponsor, joint global coordinator and joint bookrunnerΒ 

Nick Donald

Stuart Dickson

Β 

Barclays Capital Tel: +44 (0)20 7623 2323

Joint global coordinator and joint bookrunner

Jon Bathard-Smith

Tom Johnson

Derek McNulty

Β 

Collins Stewart Tel: +44 (0)20 7523 8350

Joint broker and joint bookrunner

Mark Dickenson

Bruce Garrow

Matt Goode

Β 

RBS Hoare Govett Tel: +44 (0)20 7678 8000

Joint broker and joint bookrunner

Nick Adams

Lee Morton

Β 

MHP Communications Tel: +44 (0)20 3128 8100

Andrew Jaques

John Olsen

Ian Payne

Β 

This Announcement is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or any other jurisdiction into which the same would be unlawful.

Β 

This Announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, South Africa or the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan, South Africa or the United States or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan, South Africa or the United States. The offer and sale of the securities referred to herein has not been and will not be registered under the USΒ Securities Act or under the applicable securities laws of Australia, Canada, Japan or South Africa. There will be no public offer of securities in the United States, Australia, Canada, Japan or South Africa. The availability of the Rights Issue to persons not resident in the United Kingdom may be affected by the laws of the relevant jurisdictions. Such persons should inform themselves about and observe any application requirements. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Β 

This Announcement is for information only and does not constitute or form part of any offer or invitation to issue, acquire or dispose of any securities or investment advice in any jurisdiction.

Β 

This Announcement is an advertisement and not a prospectus and investors should not subscribe for or purchase any New Ordinary Shares referred to in this Announcement in connection with Rights Issue except on the basis of information contained in the Prospectus. Copies of the Prospectus are available from the offices of the Company at TempleΒ Fields, Harlow, Essex CM20Β 2BHand on the Company's website, www.yulecatto.com (although, neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement).

Β 

HSBC which is authorised and regulated by the FSA in the United Kingdom, is acting exclusively for the Company as Sole Financial Adviser, Sole Sponsor, Joint Global Coordinator and Joint Bookrunner in connection with the Rights Issue and Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Rights Issue or any other matters referred to in this Announcement.

Β 

Barclays Capital which is authorised and regulated by the FSA in the United Kingdom, is acting exclusively for the Company as Joint Global Coordinator and Joint Bookrunner in connection with the Rights Issueand Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Rights Issue or any other matters referred to in this Announcement.

Β 

RBS Hoare Govett which is authorised and regulated by the FSA in the United Kingdom, is acting exclusively for the Company as JointΒ Bookrunner and Joint Corporate Broker in connection with the Rights Issueand Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Rights Issue or any other matters referred to in this Announcement.

Β 

Collins Stewart which is authorised and regulated by the FSA in the United Kingdom, is acting exclusively for the Company as JointΒ Bookrunner and Joint Corporate Broker in connection with the Rights Issueand Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Rights Issue or any other matters referred to in this Announcement.

Β 

Apart from the responsibilities and liabilities, if any, which may be imposed on HSBC, Barclays Capital, RBS Hoare Govett and Collins Stewart by the FSMA, each of HSBC, Barclays Capital, RBS Hoare Govett and Collins Stewart accepts no responsibility whatsoever for, and makes no representation or warranty, express of implied, in relation to, the contents of this Announcement (including its accuracy, completeness or verification) or any other statement made or purported to be made by it, or on its behalf, in connection with the Company, the securities or the Rights Issue. Each of HSBC, Barclays Capital, RBS Hoare Govett and Collins Stewart accordingly disclaims to the fullest extent permitted by law all and any responsibility and liability, whether arising in tort, contract or otherwise (save as referred to above), which it might otherwise have in respect of this announcement or any such statement.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ROIGGUQPGUPGGMM
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.